Cannabis, cannabidiol, and epilepsy - From receptors to clinical response

Epilepsy and Behavior

Volumn 41, Issue , 2014, Pages 277-282

  Szaflarski, Jerzy P ^a   Martina Bebin, E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cannabidiol (CBD); Cannabis; Cognition; Epilepsy; Medical marijuana; Seizures; Tetrahydrocannabinol (THC)

Indexed keywords

CANNABICHROMENE; CANNABIDIOL; CANNABIDIOL DERIVATIVE; CANNABIGEROL; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; CANNABIS; CANNABIS DERIVATIVE; ENDOCANNABINOID; TETRAHYDROCANNABINOL; DRONABINOL; MEDICAL CANNABIS;

ANTICONVULSANT THERAPY; COGNITION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG WITHDRAWAL; EPILEPSY; EXPERIMENTAL EPILEPSY; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; SEIZURES;

ANIMALS; CANNABIDIOL; DRONABINOL; EPILEPSY; HUMANS; MEDICAL MARIJUANA; SEIZURES;

EID: 84918584560     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2014.08.135     Document Type: Review

References (66)

1. Deitch R. Hemp - American history revisited 2003, Alegora Publishing, NYC.
2. Gold M. Marijuana 1989, Plenum Publishing Corporation, NYC.
3. Jiang H.E., Li X., Zhao Y.X., Ferguson D.K., Hueber F., Bera S., et al. A new insight into Cannabis sativa (Cannabaceae) utilization from 2500-year-old Yanghai Tombs, Xinjiang, China. J Ethnopharmacol 2006, 108(3):414-422.
4. Cohen S. Therapeutic aspects. Marihuana research findings: 1996 1977, 14:194-214. NIDA, Rockville, Maryland. R. Petersen (Ed.).
5. Gordon E., Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001, 42(10):1266-1272.
6. O'Shaughnessy W. On the preparations of Indian hemp, or gunjah. Provincial Med J 1843, 123:363-369.
7. Mathern G., Nehlig A., Sperling M. Cannabidiol and medical marijuana for the treatment of epilepsy. Epilepsia 2014, 55(6):781-782.
8. Kaplan J. Marijuana (Report of Indian Hemp Commission 1893-1894) 1969, Thos. Jefferson Publishing Company, Silver Spring, Maryland.
9. Annas G.J. Medical marijuana, physicians, and state law. N Engl J Med 2014, 371:983-985.
10. Johnson M., Devane W., Howlett A., Melvin L., Milne G. Structural studies leading to the discovery of a cannabinoid binding site. NIDA Res Monogr 1988, 90:129-135.
11. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988, 34(5):605-613.
12. Hofmann M.E., Frazier C.J. Marijuana, endocannabinoids, and epilepsy: potential and challenges for improved therapeutic intervention. Exp Neurol 2013, 244:43-50.
13. Lutz B. On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem Pharmacol 2004, 68(9):1691-1698.
14. De Petrocellis L., Cascio M.G., Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004, 141(5):765-774.
15. Robson P.J. Therapeutic potential of cannabinoid medicines. Drug Test Anal 2014, 6(1-2):24-30.
16. Russo E.B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011, 163(7):1344-1364.
17. Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008, 153(2):199-215.
18. Karler R., Cely W., Turkanis S.A. The anticonvulsant activity of cannabidiol and cannabinol. Life Sci 1973, 13(11):1527-1531.
19. Karler R., Cely W., Turkanis S.A. Anticonvulsant properties of delta 9-tetrahydrocannabinol and other cannabinoids. Life Sci 1974, 15(5):931-947.
20. Wallace M.J., Blair R.E., Falenski K.W., Martin B.R., DeLorenzo R.J. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther 2003, 307(1):129-137.
21. Wallace M.J., Martin B.R., DeLorenzo R.J. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol 2002, 452(3):295-301.
22. Wallace M.J., Wiley J.L., Martin B.R., DeLorenzo R.J. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol 2001, 428(1):51-57.
23. Consroe P., Wolkin A. Cannabidiol - antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther 1977, 201(1):26-32.
24. Jones N.A., Glyn S.E., Akiyama S., Hill T.D., Hill A.J., Weston S.E., et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 2012, 21(5):344-352.
25. Jones N.A., Hill A.J., Smith I., Bevan S.A., Williams C.M., Whalley B.J., et al. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 2010, 332(2):569-577.
26. Shirazi-zand Z., Ahmad-Molaei L., Motamedi F., Naderi N. The role of potassium BK channels in anticonvulsant effect of cannabidiol in pentylenetetrazole and maximal electroshock models of seizure in mice. Epilepsy Behav 2013, 28(1):1-7.
27. Consroe P., Benedito M.A., Leite J.R., Carlini E.A., Mechoulam R. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 1982, 83(3-4):293-298.
28. Devinsky O., Cilio M.R., Cross H., Fernandez-Ruiz J., French J., Hill C., et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014, 55(6):791-802.
29. Mechoulam R., Peters M., Murillo-Rodriguez E., Hanus L.O. Cannabidiol - recent advances. Chem Biodivers 2007, 4(8):1678-1692.
30. 2+ levels. J Neurosci 2009, 29(7):2053-2063.
31. Gloss D., Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev 2014, 3:CD009270.
32. Gloss D. Management of substance abuse 2014, World Health Organization, Cannabis, [cited 2014 August 13].
33. Sirven J.I., Drazkowski J.F., Zimmerman R.S., Bortz J.J., Shulman D.L., Macleish M. Complementary/alternative medicine for epilepsy in Arizona. Neurology 2003, 61(4):576-577.
34. Keeler M.H., Reifler C.B. Grand mal convulsions subsequent to marijuana use. Case report. Dis Nerv Syst 1967, 28(7 Pt 1):474-475.
35. Perez-Reyes M., Wingfield M. Letter: cannabidiol and electroencephalographic epileptic activity. JAMA 1974, 230(12):1635.
36. Feeney D.M. The marijuana window: a theory of cannabis use. Behav Biol 1976, 18(4):455-471.
37. Gross D.W., Hamm J., Ashworth N.L., Quigley D. Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center. Neurology 2004, 62(11):2095-2097.
38. Eisenberg D.M., Kessler R.C., Foster C., Norlock F.E., Calkins D.R., Delbanco T.L. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 1993, 328(4):246-252.
39. Hamerle M., Ghaeni L., Kowski A., Weissinger F., Holtkamp M. Cannabis and other illicit drug use in epilepsy patients. Eur J Neurol 2014, 21(1):167-170.
40. Ng S.K., Brust J.C., Hauser W.A., Susser M. Illicit drug use and the risk of new-onset seizures. Am J Epidemiol 1990, 132(1):47-57.
41. Ashton C.H. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001, 178:101-106.
42. Morgan C.J., Freeman T.P., Schafer G.L., Curran H.V. Cannabidiol attenuates the appetitive effects of delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 2010, 35(9):1879-1885.
43. Morgan C.J., Schafer G., Freeman T.P., Curran H.V. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br J Psychiatry 2010, 197(4):285-290.
44. Bolla K.I., Brown K., Eldreth D., Tate K., Cadet J.L. Dose-related neurocognitive effects of marijuana use. Neurology 2002, 59(9):1337-1343.
45. Nutt D., King L.A., Saulsbury W., Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007, 369(9566):1047-1053.
46. Ducros A., Boukobza M., Porcher R., Sarov M., Valade D., Bousser M.G. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain 2007, 130(Pt 12):3091-3101.
47. Wolff V., Armspach J.P., Lauer V., Rouyer O., Bataillard M., Marescaux C., et al. Cannabis-related stroke: myth or reality?. Stroke 2013, 44(2):558-563.
48. Hall W., Solowij N. Adverse effects of cannabis. Lancet 1998, 352(9140):1611-1616.
49. Zalesky A., Solowij N., Yucel M., Lubman D.I., Takagi M., Harding I.H., et al. Effect of long-term cannabis use on axonal fibre connectivity. Brain 2012, 135(Pt 7):2245-2255.
50. Smith A.M., Fried P.A., Hogan M.J., Cameron I. Effects of prenatal marijuana on visuospatial working memory: an fMRI study in young adults. Neurotoxicol Teratol 2006, 28(2):286-295.
51. Gruber S.A., Rogowska J., Yurgelun-Todd D.A. Altered affective response in marijuana smokers: an fMRI study. Drug Alcohol Depend 2009, 105(1-2):139-153.
52. Batalla A., Bhattacharyya S., Yucel M., Fusar-Poli P., Crippa J.A., Nogue S., et al. Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS One 2013, 8(2):e55821.
53. Fried P.A. Adolescents prenatally exposed to marijuana: examination of facets of complex behaviors and comparisons with the influence of in utero cigarettes. J Clin Pharmacol 2002, 42(11 Suppl):97S-102S.
54. Fried P., Watkinson B., James D., Gray R. Current and former marijuana use: preliminary findings of a longitudinal study of effects on IQ in young adults. CMAJ 2002, 166(7):887-891.
55. Harkany T., Guzman M., Galve-Roperh I., Berghuis P., Devi L.A., Mackie K. The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci 2007, 28(2):83-92.
56. Levin K.H., Copersino M.L., Heishman S.J., Liu F., Kelly D.L., Boggs D.L., et al. Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend 2010, 111(1-2):120-127.
57. GW Pharmaceuticals announces physician reports of Epidiolex(R) treatment effect in children and young adults with treatment-resistant epilepsy from Physician-Led Expanded Access Treatment Program 2014, [press release] http://ir.gwpharm.com/releasedetail.cfm?ReleaseID=855006.
58. Consroe P.F., Wood G.C., Buchsbaum H. Anticonvulsant nature of marihuana smoking. JAMA 1975, 234(3):306-307.
59. Maa E., Figi P. The case for medical marijuana in epilepsy. Epilepsia 2014, 55(6):783-786.
60. Ames F.R., Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J 1986, 69(1):14.
61. Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gagliardi R., et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980, 21(3):175-185.
62. Anti-epileptic action of marijuana-active substances. Federation of American Society for Experimental Biology 1949, J. Davis, H. Ramsey (Eds.).
63. Lorenz R. On the application of cannabis in paediatrics and epileptology. Neuro Endocrinol Lett 2004, 25(1-2):40-44.
64. Mechoulam R., Carlini E.A. Toward drugs derived from cannabis. Naturwissenschaften 1978, 65(4):174-179.
65. Porter B.E., Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 2013, 29(3):574-577.
66. Double blind clinical study of cannabidiol as a secondary anticonvulsant. Marijuana '90 International Conference on Cannabis and Cannabinoids 1990, International Association of Cannabinoid Medicines, Kolympari, Crete. B. Trembly, M. Sherman (Eds.).